Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Assets: 2013-2024

Historic Current Assets for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $441.0 million.

  • Ocular Therapeutix's Current Assets fell 18.19% to $387.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $387.0 million, marking a year-over-year decrease of 18.19%. This contributed to the annual value of $441.0 million for FY2024, which is 89.89% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Current Assets is $441.0 million, which was up 89.89% from $232.2 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Current Assets registered a high of $441.0 million during FY2024, and its lowest value of $129.6 million during FY2022.
  • For the 3-year period, Ocular Therapeutix's Current Assets averaged around $267.6 million, with its median value being $232.2 million (2023).
  • As far as peak fluctuations go, Ocular Therapeutix's Current Assets surged by 309.11% in 2020, and later slumped by 32.24% in 2022.
  • Ocular Therapeutix's Current Assets (Yearly) stood at $246.2 million in 2020, then declined by 22.29% to $191.3 million in 2021, then plummeted by 32.24% to $129.6 million in 2022, then spiked by 79.16% to $232.2 million in 2023, then surged by 89.89% to $441.0 million in 2024.